Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Chris Lange | Jul 29, 2015 at 12:09 PM EDT

Who Really Won in the PDL and Ariad Royalty Deal?

ThinkstockThe solid performance of the healthcare sector over the past year has been enhanced by mergers and acquisitions, licensing, and…

Chris Lange | Jul 29, 2015 at 10:18 AM EDT

GC Aesthetics Sets Expected Price Range For IPO

ThinkstockGC Aesthetics PLC filed an amended F-1 form with the Securities and Exchange Commission (SEC) for its initial public offering…

Chris Lange | Jul 29, 2015 at 8:58 AM EDT

Humana Posts 2Q Earnings Beat

ThinkstockHumana Inc. (NYSE: HUM) reported its second-quarter financial results Wednesday before the markets opened. The company had $1.67 in earnings…

Chris Lange | Jul 29, 2015 at 8:49 AM EDT

Anthem Posts Strong Second Quarter Beat

ThinkstockAnthem, Inc. (NYSE: ANTM) reported its second-quarter financial results Wednesday before the markets opened. The company had $3.10 in earnings…

Chris Lange | Jul 28, 2015 at 5:13 PM EDT

Dermira Files For Secondary Offering

ThinkstockDermira, Inc. (NASDAQ: DERM) filed an S-1 form with the Securities and Exchange Commission (SEC) for a secondary offering. There…

Chris Lange | Jul 28, 2015 at 4:54 PM EDT

Gilead Tops Estimates in 2Q

courtesy of Gilead SciencesGilead Sciences Inc. (NASDAQ: GILD) reported second-quarter financial results Tuesday after the markets closed. The biotech giant…

Chris Lange | Jul 28, 2015 at 1:47 PM EDT

NantKwest Enters the Market With a Bang

ThinkstockNantKwest (NASDAQ: NK) entered the market Tuesday with its initial public offering (IPO). The stock priced early Tuesday morning at…

Chris Lange | Jul 28, 2015 at 12:55 PM EDT

Was the Immunomedics Sell-Off Too Extreme?

ThinkstockBelgian pharmaceutical group UCB announced Tuesday morning that its phase 3 trial for lupus treatment epratuzumab failed to produce statistically…

Chris Lange | Jul 28, 2015 at 9:55 AM EDT

Are Merck Earnings Enough?

ThinkstockMerck & Co. Inc. (NYSE: MRK) reported its second-quarter financial results Tuesday before the markets opened. The pharmaceutical giant had…

Paul Ausick | Jul 28, 2015 at 7:42 AM EDT

Pfizer Overcomes Currency Exchange Issue with Stronger Sales of Cancer Drugs

ThinkstockPfizer Inc. (NYSE: PFE) reported second quarter 2015 results before markets opened Tuesday morning. The company reported quarterly adjusted diluted…

Chris Lange | Jul 27, 2015 at 4:15 PM EDT

Can Nymox Sustain This Massive Rally?

ThinkstockNymox Pharmaceutical Corp. (NASDAQ: NYMX) was one of the best performers on Monday despite a down day in the market.…

Paul Ausick | Jul 27, 2015 at 2:17 PM EDT

What to Look For in Pfizer Earnings

Wikimedia CommonsBefore the market opens on Tuesday morning, Pfizer Inc. (NYSE: PFE) is scheduled to report second-quarter results. The company…

Chris Lange | Jul 27, 2015 at 1:40 PM EDT

What to Expect from Merck Earnings

ThinkstockMerck & Co. Inc. (NYSE: MRK) reports on Tuesday morning comes into earnings with shares up only 2.7% or so…

Chris Lange | Jul 27, 2015 at 11:53 AM EDT

Have Analysts Fully Priced in Praluent to Regeneron?

ThinkstockRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NYSE: SNY) announced last Friday that the U.S. Food and Drug Administration (FDA)…

Jon C. Ogg | Jul 27, 2015 at 11:29 AM EDT

Teladoc Shares Sell Off Despite Positive Initial Analyst Coverage

ThinkstockTeladoc Inc. (NYSE: TDOC) was a hot initial public offering this summer, and shares remain 50% higher than at the…

1 … 253 254 255 256 257 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Who Really Won in the PDL and Ariad Royalty Deal?

GC Aesthetics Sets Expected Price Range For IPO

Humana Posts 2Q Earnings Beat

Anthem Posts Strong Second Quarter Beat

Dermira Files For Secondary Offering

Gilead Tops Estimates in 2Q

NantKwest Enters the Market With a Bang

Was the Immunomedics Sell-Off Too Extreme?

Are Merck Earnings Enough?

Pfizer Overcomes Currency Exchange Issue with Stronger Sales of Cancer Drugs

Can Nymox Sustain This Massive Rally?

What to Look For in Pfizer Earnings

What to Expect from Merck Earnings

Have Analysts Fully Priced in Praluent to Regeneron?

Teladoc Shares Sell Off Despite Positive Initial Analyst Coverage

Why $34,000 Is the Social Security Tax Threshold Most Retirees Never See Coming

Could This Texas Town Be America’s Most Underrated Golf Retirement Destination?

A $620,000 Portfolio That Pays More Than the Average Social Worker’s Salary

The 401(k) Bracket Smoothing Math: Why a 66 Year Old Couple With $1.5 Million Should Convert Exactly $90,000 a Year

Why $34,000 Is the Social Security Tax Threshold Most Retirees Never See Coming

The 401(k) Bracket Smoothing Math: Why a 66 Year Old Couple With $1.5 Million Should Convert Exactly $90,000 a Year

After Comparing Every Weekly Pay ETF on the Market, Roundhill’s Lineup Is the Only One Somewhat Delivering

Health and Healthcare Articles

All Health and Healthcare Articles

Who Really Won in the PDL and Ariad Royalty Deal?

GC Aesthetics Sets Expected Price Range For IPO

Humana Posts 2Q Earnings Beat

Anthem Posts Strong Second Quarter Beat

Dermira Files For Secondary Offering

Gilead Tops Estimates in 2Q

NantKwest Enters the Market With a Bang

Was the Immunomedics Sell-Off Too Extreme?

Are Merck Earnings Enough?

Pfizer Overcomes Currency Exchange Issue with Stronger Sales of Cancer Drugs

Can Nymox Sustain This Massive Rally?

What to Look For in Pfizer Earnings

What to Expect from Merck Earnings

Have Analysts Fully Priced in Praluent to Regeneron?

Teladoc Shares Sell Off Despite Positive Initial Analyst Coverage

Why $34,000 Is the Social Security Tax Threshold Most Retirees Never See Coming

Could This Texas Town Be America’s Most Underrated Golf Retirement Destination?

A $620,000 Portfolio That Pays More Than the Average Social Worker’s Salary

Featured Reads

The 401(k) Bracket Smoothing Math: Why a 66 Year Old Couple With $1.5 Million Should Convert Exactly $90,000 a Year

Why $34,000 Is the Social Security Tax Threshold Most Retirees Never See Coming